2-Cyclopentyl-4-(4-fluorophenyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7-methyl-5,6,7,8-tetrahydroquinolin-5-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-Cyclopentyl-4-(4-fluorophenyl)-3-[fluoro-[4-(trifluoromethyl)phenyl]methyl]-7-methyl-5,6,7,8-tetrahydroquinolin-5-ol
• 化学式: C₂₉H₂₈F₅NO
• 分子量: 501.5
• InChiKey: VYPKEUMWJXCGFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Combinations of Cholesterol Ester Transfer Protein Inhibitors and HMG COA Reductase Inhibitors for Cardiovascular Indications
  申请人：Keller T. Bradley

  公开号：US20070203246A1

  公开（公告）日：2007-08-30

  The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.
• [EN] COMBINATIONS COMPRISING (S)-AMLODIPINE AND A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, AND METHODS FOR REDUCING HYPERTENSION<br/>[FR] COMBINAISONS COMPRENANT (S)-AMLODIPINE ET UN INHIBITEUR DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE, ET METHODES PERMETTANT DE REDUIRE L'HYPERTENSION
  申请人：SEPRACOR INC

  公开号：WO2005117869A1

  公开（公告）日：2005-12-15

  One aspect of the present invention relates to pharmaceutical compositions comprising optically pure (S)-amlodipine and a cholesteryl ester transfer protein inhibitor. In certain embodiments, the cholesteryl ester transfer protein is torcetrapib, JTT-705, or SC-795. In a preferred embodiment, the cholesteryl ester transfer protein is torcetrapib. In certain embodiments, said optically pure (S)-amlodipine is optically pure (S)-amlodipine malate, or a polymorph, pseudopolymorph or solvate thereof. Another aspect of the present invention relates to a method of treating a patient suffering from hypertension, hyperlipidemia, or a cardiac disorder, comprising co-administering a therapeutically effective amount of optically pure (S)-amlodipine and a cholesteryl ester transfer protein inhibitor. In certain embodiments, said optically pure (S)-amlodipine is optically pure (S)­amlodipine malate, or a polymorph, pseudopolymorph or solvate thereof.